Loading...
Matching-adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed-duration venetoclax and ibrutinib in patients with treatment-naïve chronic lymphocytic leukaemia
Munir, Talha Mohseninejad, Leyla Rakonczai, Pal Dobi, Balazs Xu, Sheng Yang, Keri Vezan, Remus Calle, Nicolás Martinez
Munir, Talha
Mohseninejad, Leyla
Rakonczai, Pal
Dobi, Balazs
Xu, Sheng
Yang, Keri
Vezan, Remus
Calle, Nicolás Martinez
Abstract
no abstract available
MIDER Authors
Affiliations
Date
2025-11-11
Type
Article
Collections
Citation
Munir T, Mohseninejad L, Rakonczai P, Dobi B, Xu S, Yang K, Vezan R, Calle NM. Matching-adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed-duration venetoclax and ibrutinib in patients with treatment-naïve chronic lymphocytic leukaemia. Br J Haematol. 2026 Jan;208(1):321-324. doi: 10.1111/bjh.70241